Gene · 9100
Papers1,422
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,422
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CircNSD2 promotes metastasis and immune escape by increasing the USP10/SRSF6-mediated alternative splicing of TPM1 in TNBC. | Mol Cancer | 2026 | 41808072 | PubTator, text mining | PubMed |
| Proteasomal control of transcription factors: mechanisms, regulation and dysregulation. | Cell Mol Life Sci | 2026 | 41764121 | PubTator, text mining | PubMed |
| Extracellular Vesicles in Liver Fibrosis: Pathogenic Messengers, Diagnostic Biomarkers, and Therapeutic Nanovectors. | Pharmaceutics | 2026 | 41754972 | PubTator, text mining | PubMed |
| Research Progress on the Biological Function, Disease-Driving Mechanism and Clinical Targeting Strategies of G3BP2. | Molecules | 2026 | 41752399 | PubTator, text mining | PubMed |
| A Brief Progress in Methods for Deciphering Protein-Protein Interaction Networks. | Int J Mol Sci | 2026 | 41751977 | PubTator, text mining | PubMed |
| Distinct Regulatory Genomic Architectures Distinguish Early-Onset from Late-Onset Alzheimer's Disease. | Genes (Basel) | 2026 | 41751570 | PubTator, text mining | PubMed |
| PCMTD1-127aa suppresses osteosarcoma progression by competitively binding to USP10 to promote c-MYC degradation. | iScience | 2026 | 41732254 | PubTator, text mining | PubMed |
| Phosphorylation of FBXL3 mediates GLDC polyubiquitination to suppress MHC-I expression and promote cancer immune evasion. | Cell Insight | 2026 | 41728086 | PubTator, text mining | PubMed |
| The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications. | Front Immunol | 2026 | 41727427 | PubTator, text mining | PubMed |
| Ubiquitin-Specific Protease 10: A New Target in Tumor Immune Escape. | Cancer Control | 2026 | 41711750 | PubTator, text mining | PubMed |
| RNA-binding motif protein 15 promotes gastric cancer growth and drug resistance via USP10-mediated deubiquitination and stabilization of nuclear NRF2. | Drug Resist Updat | 2026 | 41702032 | PubTator, text mining | PubMed |
| Spotlights on ubiquitin-specific proteases in lung cancer: from multifaceted pathophysiological mechanisms to potential therapeutic targets. | PeerJ | 2026 | 41635813 | PubTator, text mining | PubMed |
| USP10-mediated deubiquitination and activation of KRAS mutants promotes colorectal cancer via a novel USP10/KRAS positive feedback circuit. | Acta Pharm Sin B | 2026 | 41584349 | PubTator, text mining | PubMed |
| YTHDC1 Inhibits Esophageal Cancer Cell Apoptosis, Radiosensitivity and Autophagy Via Upregulating PLK1 by Stabilizing USP10. | Appl Biochem Biotechnol | 2026 | 41579257 | PubTator, text mining | PubMed |
| Downregulation of the deubiquitinating enzyme USP10 correlates with neuronal apoptosis in HTLV-1-associated myelopathy. | Sci Rep | 2026 | 41577957 | PubTator, text mining | PubMed |
| Obestatin Treatment Counteracts Muscle Wasting by Reactivation of Autophagy in Duchenne Muscular Dystrophy. | MedComm (2020) | 2026 | 41541654 | PubTator, text mining | PubMed |
| Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma. | Nat Commun | 2026 | 41535264 | PubTator, text mining | PubMed |
| Co-targeting MRPS7-23 synergistically enhances cisplatin efficacy to suppress nasopharyngeal carcinoma growth and metastasis. | Int J Biol Sci | 2026 | 41522354 | PubTator, text mining | PubMed |
| USP10 promotes glioma stem cell maintenance and glioblastoma growth by antagonizing DTX3L-mediated SATB2 ubiquitination. | Nat Commun | 2026 | 41507172 | PubTator, text mining | PubMed |
| NUP62 Elevates USP10 Expression and Promotes Tamoxifen Resistance of Breast Cancer by Deubiquitinating ERα. | Ann Surg Oncol | 2026 | 41501594 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9100/papers?page=3